Home
»
2016
»
November

Arrowhead, Amgen license and collaboration agreement closed

American Pharmacy News Reports | Nov 23, 2016

The agreement failed because of the early termination waiting period.

The agreement failed because of the early termination waiting period. | File image

Arrowhead Pharmaceuticals has closed the license and collaboration agreement with Amgen regarding the RNAi ARC-LPA program.
The agreement fell through because of the early termination of the waiting period according to the Hart-Scott Rodino Antitrust Improvements Act of 1976.

More News

State Issues South Dakota issues air quality alert due to elevated PM2.5 levels Aug 3, 2025

Regulatory CEO of Empower Pharmacy: 'The smear campaign against compounded GLP-1s was never about safety' Jul 31, 2025

State Issues NCPA supports new bill allowing Medicare reimbursement for pharmacist services Jul 25, 2025

State Issues NCPA announces finalists for 2025 student business plan competition Jul 24, 2025

PhRMA executive on 340B costs: ‘The more hospitals use 340B as a profit center, the more Medicaid loses’ Jul 23, 2025

State Issues Michigan Department launches "LARA Living Room" podcast on state regulations Jul 22, 2025